Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2014 Results
Date:8/7/2014

WASHINGTON, Aug. 7, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the second quarter ended June 30, 2014.

"We are encouraged by the early positive reception of HETLIOZ by patients, physicians and payors. We look forward to more patients benefiting from HETLIOZ in the coming months and years," said Mihael Polymeropoulos MD, President and CEO of Vanda Pharmaceuticals.

Key Highlights:

  • As of August 6, 2014, over 420 new patient prescriptions have been written for  HETLIOZ®(tasimelteon) in the U.S.
  • In June 2014, Vanda announced that the European Medicines Agency (EMA) accepted for evaluation the Marketing Authorization Application for oral HETLIOZ® capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
  • In July 2014, the U.S. Patent and Trademark Office (USPTO) issued a new method of use patent for HETLIOZ®  in the treatment of Non-24.
  • SECOND QUARTER 2014 REPORTED RESULTSTotal revenues for the second quarter of 2014 were $10.9 million, compared to $9.1 million for the first quarter of 2014 and $8.3 million for the second quarter of 2013.  Net product revenues related to U.S. sales of HETLIOZ® in the second quarter of 2014 were $1.6 million.Total operating expenses for the second quarter of 2014 were $32.5 million, compared to $35.7 million for the first quarter of 2014 and $11.7 million for the second quarter of 2013.  Vanda recorded a net loss of $21.6 million for the second quarter of 2014, compared to a net loss of $26.5 million for the first quarter of 2014 and $3.4 million
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
    2. Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
    3. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
    4. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    5. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
    6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    7. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
    8. Vanda Pharmaceuticals, Inc. Sued by Investor
    9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
    11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... , May 28, 2015  Pharmaceutic Labs ... Facility" under section 503B of the FDA,s Drug ... title, the company is subject to Current Good ... bulk medications according to the highest standards of ... Part 211. To continuously comply with FDA regulations ...
    (Date:5/28/2015)... 2015 The global departmental PACS market ... , Europe , Asia ... departmental PACS market is expected to reach $3,807.4 million by ... Browse through the TOC of global departmental PACS ... segments, with help of various tables and figures. ...
    (Date:5/28/2015)... , May 28, 2015  Janssen Pharmaceuticals, Inc. (Janssen) ... initiation of CALLISTO, a new comprehensive clinical research program ... active cancer. The studies are evaluating the medicine for ... patients with a wide range of cancer types. ... venous thromboembolism (VTE), which is a blood clot in ...
    Breaking Medicine Technology:Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 2Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 3New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 2New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 3New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 4New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 5New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 6New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 7New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 8New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 9New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 10New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 11New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 12
    (Date:5/28/2015)... 28, 2015 Ticket Down is a reputable ... between Mexico and Argentina in early September. , ... will compete on the pitch at AT&T Stadium in Arlington/Dallas, ... an international friendly on Tuesday, September 8th at 9 p.m. ... in the world including some of the most loved players ...
    (Date:5/28/2015)... 28, 2015 ZH Healthcare (ZH), a ... it is releasing BlueEHS, the Electronic Health Solution, on ... for the benefit of all AWS users worldwide. ... first of its kind, Freemium, SaaS, Electronic Health Solution ... (EHR) with an integrated practice management system (PMS), e-Rx, ...
    (Date:5/28/2015)... TX (PRWEB) May 28, 2015 Dr. ... cosmetic surgeons , has announced that the new Houston ... The American Association of Accreditation of Ambulatory Surgery Facilities ... surgery center . , According to Dr. Vitenas, ... meeting the standards of a Class C ambulatory surgery ...
    (Date:5/28/2015)... 2015 The Khanna Vision Institute announced ... application to make learning about treatment of keratoconus ... few years. This proliferation of treatment techniques has not ... of the nuances of the cutting edge technologies. Dr.Khanna, ... websites can be boring and printed material can be ...
    (Date:5/28/2015)... lifeIMAGE announced today that ... led by Cambia Health Solutions (Portland, Ore.), ... health care by creating a person-focused and economically sustainable ... for exchanging medical imaging, will use this financing to ... breadth of its network capabilities and implement the next ...
    Breaking Medicine News(10 mins):Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 2Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 3Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
    ... A study published in the October 15 issue ... the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed ... The study, led by James C. Spilsbury, PhD, of ... Ohio, focused on a subsample of 411 adolescents between ...
    ... 11:30 am EDT, TEL AVIV, Israel, October 15 ... that it has signed,an agreement to acquire 100% of ... Blessing Biotech GmbH (together the "Gewurzmuller,Group"), in consideration for ... The Company will be hosting a conference call ...
    ... Island Hospital and Brown University researchers reported that 18 percent ... initial psychiatric clearance for the surgery. The study is the ... for surgery, and the largest to determine the percentage of ... exclusion. It was published in the October edition of the ...
    ... of ills such as heart disease , , SUNDAY, ... collections of genetic and clinical data available free to ... Institutes of Health. , The Web-based SHARe (SNP Health ... from a number of large population-based studies, starting with ...
    ... breathing disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay ... airway pressure (CPAP) to treat people with obstructive sleep ... of the arteries -- within months, a new study ... of a direct link between obstructive sleep apnea and ...
    ... BEACH, Calif., Oct. 12 History,will be written if ... Act during a vote scheduled for next week. It ... law regarding swimming pool and spa safety.,The National Drowning ... but with wording similar to HR 1721 passed on ...
    Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007 2Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:NDPA Urges Passage of Historic Pool Bill 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: